News Quantified

CDXS – codexis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics [CBS News]

Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer [Yahoo! Finance]

Codexis Announces Signing of Lease for GMP Manufacturing Facility [Yahoo! Finance]

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis (NASDAQ:CDXS) was downgraded by analysts at Wall Street Zen

-17.0%

MISS

-2.2%

BEAT

1.6%

MISS

-22.1%

MISS

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: Opaleye Management Inc.

Form 4 CODEXIS, INC. For: Nov 26 Filed by: Opaleye Management Inc.

Form 4 CODEXIS, INC. For: Nov 21 Filed by: WOLF DENNIS P

Form 144 CODEXIS, INC. Filed by: WOLF DENNIS P

Form 4 CODEXIS, INC. For: Nov 13 Filed by: MOORE ALISON

Top News Gainers

3/23 Codexis, Inc. (NASDAQ: CDXS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 12.1%

3/23 Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders 11.0%

11/5 Q3/2019 9/30/2019 EPS 0.040 ZacksConsensus -0.090 ActVsEst 0.130 - Beat 9.4%

8/26 Form 4 CODEXIS, INC. For: Aug 22 Filed by: Yang Patrick Y 7.7%

4/3 Form 4 CODEXIS, INC. For: Apr 01 Filed by: BARUCH THOMAS R 6.6%

3/27 Form 4 CODEXIS, INC. For: Mar 25 Filed by: WOLF DENNIS P 5.7%

3/4 Codexis, Inc. (NASDAQ: CDXS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.6%

3/5 Codexis, Inc. (NASDAQ: CDXS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 4.8%

4/8 Codexis, Inc. (NASDAQ: CDXS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 4.3%

9/4 Form 4 CODEXIS, INC. For: Sep 03 Filed by: Yang Patrick Y 3.6%

Top News Decliners

8/6 Form 10-Q CODEXIS, INC. For: Jun 30 -18.3%

2/28 Codexis, Inc. (NASDAQ: CDXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.50 price target on the stock. -12.2%

5/7 Codexis, Inc. (CDXS) CEO John Nicols on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.2%

4/15 Near a 2-Year Low, Is Codexis Stock a Buy? [The Motley Fool] -7.1%

5/10 Codexis, Inc. (NASDAQ: CDXS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.5%

12/24 Codexis, Inc. (NASDAQ: CDXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.50 price target on the stock. -5.2%

2/25 Codexis to Present at Two Investment Conferences in March -4.1%

5/22 Codexis (CDXS) Presents At UBS Global Healthcare Conference - Slideshow [Seeking Alpha] -3.9%

4/23 Form 4 CODEXIS, INC. For: Apr 21 Filed by: KELLEY BERNARD J -3.6%

7/23 Form 8-K CODEXIS, INC. For: Jul 19 -3.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day